Adverse Reactions Adverse reactions observed with NovoLog include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus
The process is designed to be immediate
By approaching the transition with structure and patience, patients increase their likelihood of long-term success with whichever therapy proves most effective for them
it does not establish that reducing to 0.5 or 1.0 mg will hold the same plateau. One milligram has direct weight-loss evidence as an assigned treatment arm in type 2 diabetes, while small uncontrolled series suggest that dose reduction or reduced-frequency dosing can sometimes hold a plateau. No trial has established a Semaglutide step-down schedule
Single nucleotide polymorphisms in the intergenic region between metformin transporter OCT2 and OCT3 coding genes are associated with short-term response to metformin monotherapy in type 2 diabetes mellitus patients
As more research emerges, we continue to refine our approaches to managing side effects and improving patient outcomes